Banco Macro SA Receives Neutral Rating from JPMorgan Chase & Co. (BMA)

Share on StockTwits

JPMorgan Chase & Co. restated their neutral rating on shares of Banco Macro SA (NYSE:BMA) in a report released on Wednesday. JPMorgan Chase & Co. currently has a $38.00 price objective on the stock, up from their previous price objective of $28.00.

JPMorgan Chase & Co. has also taken action a number of other financials stocks recently. The firm downgraded shares of Grupo Financiero Galicia S.A. to an underweight rating. Also, JPMorgan Chase & Co. reiterated its neutral rating on shares of Teva Pharmaceutical Industries Ltd (ADR). They have a $56.00 price target on that stock, up previously from $55.00.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Banco Macro SA from an outperform rating to a neutral rating in a research note on Tuesday, May 20th. They now have a $35.00 price target on the stock.

Banco Macro SA (NYSE:BMA) traded down 0.46% during mid-day trading on Wednesday, hitting $34.49. The stock had a trading volume of 74,448 shares. Banco Macro SA has a one year low of $13.63 and a one year high of $37.99. The stock’s 50-day moving average is $31.56 and its 200-day moving average is $26.61. The company has a market cap of $2.016 billion and a P/E ratio of 5.19.

Banco Macro SA (NYSE:BMA) last issued its quarterly earnings data on Thursday, May 22nd. The company reported $2.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.68 by $0.85. On average, analysts predict that Banco Macro SA will post $6.32 earnings per share for the current fiscal year.

Banco Macro SA (NYSE:BMA) is an Argentina-based bank.

To view JPMorgan Chase & Co.’s full report, visit JPMorgan Chase & Co.’s official website.

Receive News & Ratings for Banco Macro SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Banco Macro SA and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Investment Analysts’ Downgrades for September, 29th
Investment Analysts’ Downgrades for September, 29th
Stock Analysts’ Upgrades for September, 29th
Stock Analysts’ Upgrades for September, 29th
Receptos Hits New 52-Week High at $67.34
Receptos Hits New 52-Week High at $67.34
FedEx Reaches New 12-Month High at $162.33
FedEx Reaches New 12-Month High at $162.33
NiSource Hits New 52-Week High at $41.12
NiSource Hits New 52-Week High at $41.12
Ambit Biosciences Corp Earns Positive Rating from Roth Capital
Ambit Biosciences Corp Earns Positive Rating from Roth Capital


Leave a Reply

 
© 2006-2014 Mideast Time.